Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab

Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab

Abstract Background A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving...

Full description

Bibliographic Details
Main Authors: Christopher A. Turski, Mitchell A. Jacobs, Michelle M. Abou-Jaoude, Nicholas H. Fowler, Ryan Harpole, Emily Altman, John B. Chadwell, Gabriel Kindl, Hayley R. James, Shivani V. Reddy, Ramiro S. Maldonado
Format: Article
Language:English
Published: BMC 2022-11-01
Series:International Journal of Retina and Vitreous
Subjects:
Anti-VEGF
Bevacizumab
Center-involving diabetic macular edema
Central subfield thickness
Responders
Non-responders
Online Access:https://doi.org/10.1186/s40942-022-00430-z

Internet

https://doi.org/10.1186/s40942-022-00430-z

Similar Items